CO₂ angiography uses medical-grade carbon dioxide as a gaseous contrast agent to visualise blood vessels, mainly in the limbs, abdomen and pelvis. It is an important option for people with chronic kidney disease, diabetes, previous acute kidney injury or an allergy to iodinated contrast, and for vascular teams seeking to reduce iodine exposure.
CO₂ does not replace iodine in every examination, nor does it eliminate all procedural risks. However, when used in the appropriate vascular territory, with a controlled injection system and by trained professionals, it enables contrast-sparing strategies, that is, using less iodine, or Zero Contrast in selected cases.
Angiography is an examination or interventional procedure in which a contrast agent is injected into the blood vessels and X-ray images are acquired. In CO₂ angiography, the contrast agent is medical-grade carbon dioxide: the gas temporarily displaces blood in the vessel and makes the vascular lumen visible on digital images.
CO₂ is eliminated mainly by the lungs through breathing. Unlike iodinated contrast, it is not filtered by the kidneys and has no direct renal toxicity. This makes it particularly useful in peripheral angiography and in certain aortic procedures performed below the diaphragm.
Iodinated contrast provides high-quality images in many anatomical regions and is often essential during specific procedural steps. In vulnerable patients, however, iodine exposure can contribute to contrast-associated acute kidney injury. The risk increases particularly in the presence of chronic kidney disease, diabetes, dehydration, heart failure, haemodynamic instability or high cumulative iodine doses.
It is helpful to distinguish between the terms. AKI stands for acute kidney injury: a rapid decline in kidney function, assessed mainly through blood creatinine and urine output. CKD stands for chronic kidney disease. eGFR, or estimated glomerular filtration rate, indicates how effectively the kidneys filter the blood: a lower value calls for more careful planning.
CO₂ reduces or avoids the iodine load and therefore removes a specific source of renal risk. It does not, however, guarantee that AKI will not occur: hypotension, bleeding, infection, embolisation, nephrotoxic drugs and pre-existing clinical conditions can damage the kidneys regardless of the contrast agent.
CO₂ is used mainly to study and treat the arteries of the lower limbs, the iliac vessels, the abdominal aorta and certain visceral or renal territories, depending on the clinical indication. It can support peripheral revascularisation, assessment of limb ischaemia, vascular access procedures and, in experienced centres, some steps of endovascular aortic repair such as EVAR, FEVAR or BEVAR.
The choice depends on the clinical question, the anatomy, the image quality achievable and the patient’s condition. In many cases the most appropriate pathway is not “CO₂ only” or “iodine only”, but a hybrid protocol: CO₂ as the primary agent, with small, targeted amounts of iodine when needed to complete the procedure safely.
The main advantage of CO₂ is the ability to significantly limit exposure to iodinated contrast in patients at high renal risk. This can make necessary vascular procedures more accessible even when kidney function is impaired and the team wants to preserve as much of the remaining renal reserve as possible.
CO₂ contains no iodine and does not cause allergic reactions to iodinated contrast. However, anyone who has had an allergic reaction should always inform their doctor: allergy and anaesthesia assessment remains essential, because drugs, disinfectants, latex and other materials can cause reactions unrelated to the contrast agent.
CO₂ is not suitable for all vascular territories. As a rule, it is not used for angiography above the diaphragm, including the coronary and cerebral arteries, because gas embolisation in these areas can have serious consequences. The injection site and technical approach must be rigorously assessed by the specialist.
Image quality with CO₂ may be lower in certain vessels or conditions, for example in the presence of bowel movement, very slow flow or complex anatomy. Specific precautions are also needed in patients with cardiac or pulmonary shunts, significant pulmonary hypertension, severe respiratory disease or other conditions that the team will assess individually.
During injection, some patients report a brief sensation of warmth, pressure or discomfort. Significant pain, persistent symptoms or any feeling of being unwell should be reported immediately. Safety depends on patient selection, appropriate volumes and intervals, prevention of air contamination, monitoring and the team’s expertise.
There is no single price for CO₂ angiography in Italy or in Europe. The cost depends on the procedure, the hospital stay, the angiography system, the injection device, consumables, case complexity and the fees applied by the public or private facility.
The economic assessment should not be limited to the cost of the contrast agent. For a hospital, outcomes matter too: preventing or reducing renal complications may mean less monitoring, a lower likelihood of prolonged hospital stays, less need for nephrology treatment and fewer readmissions. These benefits must be measured in each individual centre using clinical and organisational data, not taken for granted.
Kidney protection begins before the procedure. The doctor assesses creatinine and eGFR, history of AKI, diabetes, heart failure, current medications and the actual need for iodinated contrast. When indicated, the nephrologist, interventional radiologist, vascular surgeon and anaesthetist work together to define the safest plan.
Looking for a qualified vascular centre means checking more than whether CO₂ is available. A reliable service has interventional radiology or vascular surgery with experience in peripheral procedures, written protocols for patients with reduced kidney function, suitable technology and collaboration with nephrology and anaesthesia when needed.
When contacting the centre, it is useful to ask whether they regularly perform CO₂ angiography below the diaphragm, for which indications, how they assess eGFR and AKI risk, whether they use contrast-sparing protocols and how they manage any complications. Seeking a second opinion at a high-volume centre is reasonable when the procedure is complex or kidney function is severely impaired.
Bring your most recent creatinine and eGFR results, a complete list of your medications, vascular reports and documentation of any previous reactions to contrast. This information helps the team estimate renal risk and choose the most appropriate technique.
Ask whether the procedure can be planned with CO₂, with a combination of CO₂ and low doses of iodine, or with another technique. The answer should take into account the territory to be treated and the clinical goal, not just the availability of the technology.
Before the examination, clarify which symptoms to report, whether kidney function checks are planned and whom to contact after discharge. Follow the instructions given by the centre and do not change your medication on your own.
Yes, CO₂ angiography is a useful strategy for reducing or avoiding iodinated contrast in patients with impaired kidney function, especially in vascular procedures below the diaphragm. CO₂ is not directly nephrotoxic because it is eliminated by the lungs. Overall safety, however, depends on the patient’s condition, the territory treated and the centre’s experience.
No, CO₂ does not always replace iodinated contrast. It is particularly suited to peripheral and abdominal vessels, while it is not indicated for coronary or cerebral vessels. In many complex procedures, the safest choice is a hybrid approach that uses CO₂ as the primary contrast agent and iodine in limited, targeted amounts.
Patients who need a peripheral vascular procedure and have reduced eGFR, chronic kidney disease, diabetes, previous acute kidney injury or an allergy to iodinated contrast should ask for an assessment. The final decision rests with the interventional radiologist or vascular surgeon, after evaluating the indication, anatomy and contraindications.
CO₂ injection may cause a brief, transient sensation of warmth, pressure or discomfort. The degree of discomfort varies depending on the territory treated and the individual. The team monitors the patient during the procedure and should be told immediately if the discomfort is intense or persists.
A qualified centre can explain which procedures it performs with CO₂, how it selects patients and how it manages renal risk. It should have an experienced vascular team, contrast-sparing protocols, adequate monitoring and links with nephrology when indicated. It is appropriate to ask about the team’s experience, the technology used and the follow-up pathway.
For facilities planning to develop a renal preservation programme, Angiodroid supports the evaluation of CO₂ workflows, team training and the adoption of traceable protocols for peripheral angiography. Request a clinical and organisational consultation to assess indications, training requirements and outcome metrics suited to your department.